Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

Bayani, J.; Poncet, C.; Crozier, C.; Neven, A.; Piper, T.; Cunningham, C.; Sobol, M.; Aebi, S.; Benstead, K.; Bogler, O.; Lago, L. dal; Fraser, J.; Hilbers, F.; Hedenfalk, I.; Korde, L.; Linderholm, B.; Martens, J.; Middleton, L.; Murray, M.; Kelly, C.; Nilsson, C.; Nowaczyk, M.; Peeters, S.; Peric, A.; Porter, P.; Schroder, C.; Rubio, I.T.; Ruddy, K.J.; Asperen, C. van; Weyngaert, D. van den; Deurzen, C. van; Leeuwen-Stok, E. van; Vermeij, J.; Winer, E.; Giordano, S.H.; Cardoso, F.; Bartlett, J.M.S.

doi:doi:10.1038/s41523-021-00301-0

Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 {retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString (TM) panel comprised of the genes from the commercial risk tests Prosigna (R), OncotypeDX (R), and MammaPrint (R), risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we...Show moreMale breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 {retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString (TM) panel comprised of the genes from the commercial risk tests Prosigna (R), OncotypeDX (R), and MammaPrint (R), risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.Show less

Leiden University Scholarly Publications

View statistics

Documents

In Collections

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer